A phase i study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1096-1106

  Fukutomi, Akira ^a   Hatake, Kiyohiko ^b   Matsui, Kaoru ^c   Sakajiri, Sakura ^b   Hirashima, Tomonori ^c   Tanii, Hiromi ^d   Kobayashi, Ken ^d   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

Cutaneous T cell lymphoma; Histone deacetylase inhibitors; Panobinostat; Phase 1 clinical trials

Indexed keywords

PANOBINOSTAT;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; COLON ADENOCARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; FEVER; HUMAN; JAPANESE; LARYNX SQUAMOUS CELL CARCINOMA; LEIOMYOSARCOMA; LIMB PAIN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PRURITUS; RECTUM CARCINOMA; SIDE EFFECT; SKIN LYMPHOMA; SMALL INTESTINE CANCER; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTOPENIA; THYMUS CANCER; THYROTROPIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD CELL COUNT; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84864349146     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9666-9     Document Type: Article

References (20)

1. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. doi:10.1038/nrd2133 (Pubitemid 44348499)
2. Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969. doi:10.1158/1078-0432.CCR- 08-2785
3. Atadja P (2009) Development of the pan-DAC inhibitor panobi-nostat (LBH589): successes and challenges. Cancer Lett 280:233-241. doi:10.1016/j.canlet.2009.02.019
4. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid deriva-tive LBH589. Clin Cancer Res 12:634-642. doi:10.1158/1078-0432.CCR-05-1132 (Pubitemid 43166159)
5. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173. doi:10.1200/JCO.2005.01.9679 (Pubitemid 46630509)
6. Shao W, Growney J, Feng Y, Wang P, Yan-Neale Y, O'Connor G, Kwon P, Yao Y Fawell S, Atadja P (2008) Potent anticancer activity ofapan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. AACR Meeting Abstracts 2008:735
7. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510. doi:10.1158/1078-0432.CCR-07-4262
8. Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, Masson E, Culver KW, Burris HA III, Beck J (2007) Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. ASCO Meet Abstr 25:3500
9. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC, Bexarotene Worldwide Study Group (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multi-national phase II-III trial results. J Clin Oncol 19:2456-2471 (Pubitemid 32391217)
10. Woo MM, Culver K, Li W, Liu A, Scott J, Parker K, Jalaluddin M, Laird G, Cooper MR, Schran HF (2008) Panobinostat (LBH589) pharmacokinetics (PK): implication for clinical safety and efficacy Ann Oncol 19:487P
11. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468. doi:10.1200/JCO.2009.22.1291
12. Chang AN, Cantor AB, Fujiwara Y, Lodish MB, Droho S, Crispino JD, Orkin SH (2002) GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci USA 99:9237-9242. doi:10.1073/pnas.142302099 (Pubitemid 34764597)
13. Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S (2007) Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 571:88-96. doi:10.1016/j.ejphar.2007.06.015 (Pubitemid 47379689)
14. Bates SE, Rosing DR, Fojo T, Piekarz RL (2006) Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res 12:3871-3874. doi:10.1158/1078-0432.CCR-06-1017 (Pubitemid 44078067)
15. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362-3371. doi:10.1200/JCO.2006.09.6925 (Pubitemid 47325624)
16. Weber HA, Tai F, Paul S, Schindler J, Woo MM, Spence S, Marlowe J, Lin R (2009) QT interval measurements in patients with hematologic malignancies and solid tumors treated with oral panobinostat (LBH589). ASH Annu Meet Abstr 114:3781
17. Witt O, Monkemeyer S, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A (2003) Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101:2001-2007. doi:10.1182/blood-2002-08- 2617 (Pubitemid 36237607)
18. Wolk M, Martin JE, Reinus C (2006) Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues. J Clin Pathol 59:598-602. doi:10.1136/jcp.2005.029934 (Pubitemid 43886043)
19. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147:97-101. doi:10.1111/j.1365-2141.2009.07837.x
20. San-Miguel JF, Sezer O, Siegel D, Guenther A, Mateos M, Prosser I, Cavo M, Blade J, Boccadoro M, Bengoudifa BR, Klebsattel M, Bourquelot PM, Anderson KC (2009) A Phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma. ASH Annu Meet Abstr 114:3852